“Technology grows and grows,” as one lab director explained. “Our job is to keep up with it and use it in the most efficient and effective way.”

As TAVR continues to gain popularity, researchers remain focused on discovering new ways to predict short- and long-term outcomes. One recent study, for example, explored the potential of AI-enabled imaging assessments. Another analysis focused on the CALLY index.

Cerebral embolic protection devices are "compelling," researchers wrote, but current data does not suggest they make a significant impact on patient outcomes.

Both treatment options are effective, but metabolic and bariatric surgery was linked to more significant cardiovascular risk reductions than GLP-1 medications.

When a TAVR valve fails and that patient undergoes redo TAVR, are there benefits to choosing one device type over the other? The team behind a new study tracked multiple outcomes and identified specific factors that may help predict survival. 

The move, once finalized, helps Johnson & Johnson add multiple FDA-approved technologies to its EP portfolio.

Photon flash therapy is an experimental treatment that delivers an ultrahigh dose rate of radiotherapy 100 times faster than currently available options.

Mina Chung, MD, who just concluded a one-year term as Heart Rhythm Society's president, spoke to Cardiovascular Business about successes from the past year as well as her goals for the future.